Cardiol Therapeutics expands Phase III MAVERIC trial to up to 150 patients for CardiolRx in recurrent pericarditis
CRDL•MAVERIC trial expanded after early enrollment and lower-than-expected recurrences
Cardiol Therapeutics expanded its Phase III MAVERIC trial of CardiolRx in recurrent pericarditis to up to 150 patients.
- The original 110-patient enrollment target was reached ahead of the end-of-September timetable.
- A blinded review showed fewer recurrences than expected, prompting the expansion to support a clearer efficacy readout.
- Topline results have not been presented yet; the company now expects them in mid-2027, later than prior Q1 2027 guidance.
- Management expects existing capital to fund completion, extending cash runway into Q1 2028.
